DeepTag-GPRC5D Targeted CAR T-cells

Phase 1Cell therapy

DeepTag-GPRC5D Targeted CAR T-cells is one of 39 biologic programs targeting Multiple Myeloma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaRecruiting

Multiple MyelomaPhase 1

Recruiting

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

Venclexta

AbbVie

Phase 3

17 3

Keytruda

Merck & Co.

Phase 3

17 4

Opdivo

Bristol-Myers Squibb

Phase 3

11 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 6

Treanda

AAzurity Pharmaceuticals

Phase 3

19 7

Neulasta

Amgen

Phase 3

5 8

Cytosar

Teva

Phase 3

4 9

Busulfex

Akero Therapeutics

Phase 3

14 10

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Recruiting·HHe Huang·Phase 1·NCT06084962·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DeepTag-GPRC5D Targeted CAR T-cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DeepTag-GPRC5D Targeted CAR T-cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DeepTag-GPRC5D Targeted CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — He Huang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: HHe Huang

DeepTag-GPRC5D Targeted CAR T-cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News